Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.79 |
| ▸ | RAB9A | P51151 | 4/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2088837 | 0.93 | MAPT (0.79) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL7402196 | 0.91 | MAPT (0.77) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL23986310 | 0.91 | MAPT (0.66) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL28299756 | 0.91 | MAPT (0.66) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL1794811 | 0.90 | MAPT (0.74) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL1951546 | 0.89 | MAPT (1.00) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL7598720 | 0.88 | MAPT (0.72) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL2469151 | 0.87 | MAPT (0.89) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| Methylparaben SCHEMBL31086508 | 0.87 | MAPT (0.70) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL4757010 | 0.85 | MAPT (0.72) | MAPTRAB9AL3MBTL1TDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3981906-A | Process for preparing alkyl 4,4'-(ethylenedioxy)bis-benzoates | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JA) | 1976-09-21 | — | — | US | claimed |
| US-11022604-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2021-06-01 | — | — | US | disclosed |
| US-11022604-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2020-02-27 | — | — | US | disclosed |
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2020-02-27 | — | — | US | disclosed |
| US-6756388-B1 | HAVING PIPERIDINYL AND PHENOLIC FUNCTIONALITY; BONE LOSS; BREAST OR PROSTATE CANCER | PFIZER INC. | 2004-06-29 | — | — | US | disclosed |
| US-6090949-A | Processes for preparing benzothiophenes | ELI LILLY AND COMPANY (US) | 2000-07-18 | — | — | US | disclosed |
| CN-1253556-A | Process for preparing benzothiophenes | LILLY CO ELI (US) | 2000-05-17 | — | — | CN | disclosed |
| WO-1998049156-A1 | PROCESSES FOR PREPARING BENZOTHIOPHENES | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| EP-0875510-A1 | Process for preparing benzothiophenes | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
| CN-1133040-A | Benzothiophenes and related compounds as estrogen agonists | PFIZER (US) | 1996-10-09 | — | — | CN | disclosed |
| EP-0723537-A1 | BENZOTHIOPHENES AND RELATED COMPOUNDS AS ESTROGEN AGONISTS | PFIZER INC. (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995010513-A1 | BENZOTHIOPHENES AND RELATED COMPOUNDS AS ESTROGEN AGONISTS | PFIZER INC. (US) | 1995-04-20 | — | — | WO | disclosed |
| CN-1019801-B | Antiarrhythmic and preparation method thereof | PFIZER LTD (GB) | 1992-12-30 | — | — | CN | disclosed |
| EP-0245997-B1 | N-SUBSTITUTED P-AMINOETHYLSULPHON ANILIDES AS ANTIARRHYTHMIC AGENTS, AND INTERMEDIATES THEREFOR | Pfizer Limited (GB) | 1992-04-15 | — | — | EP | disclosed |
| US-5079248-A | Antifibrillatory agents; side effect reduction | PFIZER INC. (US) | 1992-01-07 | — | — | US | disclosed |
| US-4959366-A | Anti-arrhythmic agents | PFIZER INC. (US) | 1990-09-25 | — | — | US | disclosed |
| EP-0245997-A2 | N-substituted p-aminoethylsulphon anilides as antiarrhythmic agents, and intermediates therefor | Pfizer Limited (GB) | 1987-11-19 | — | — | EP | disclosed |
| CN-87103300-A | Antiarrhythmic and preparation method thereof | — | 1987-11-11 | — | — | CN | disclosed |
| US-3981906-A | Process for preparing alkyl 4,4'-(ethylenedioxy)bis-benzoates | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JA) | 1976-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | ILK, LRRC47, RPL37 | MAPT 1188/4885RAB9A 915/4885L3MBTL1 590/4885 |
| US-11022604-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | ILK, LRRC47, RPL37 | MAPT 1188/4885RAB9A 915/4885L3MBTL1 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.